APA (7th ed.) Citation

Aldardeer, N. F., Labban, H. M., Alhuthil, R. T., Aljahdali, S. H., Alharbi, M. H., Alharbi, R. A., . . . Almangour, T. A. (2024). Effectiveness of traditional non-carbapenem β-lactams vs. novel β-lactams for the treatment of carbapenem-resistant Pseudomonas aeruginosa. BMC Infectious Diseases, 24(1), 1. https://doi.org/10.1186/s12879-024-10365-5

Chicago Style (17th ed.) Citation

Aldardeer, Namareq F., Hatun M. Labban, Raghad T. Alhuthil, Seham H. Aljahdali, Moataz H. Alharbi, Riham A. Alharbi, Mohammed I. Al Musawa, Abdulrahman A. Almalki, and Thamer A. Almangour. "Effectiveness of Traditional Non-carbapenem β-lactams Vs. Novel β-lactams for the Treatment of Carbapenem-resistant Pseudomonas Aeruginosa." BMC Infectious Diseases 24, no. 1 (2024): 1. https://doi.org/10.1186/s12879-024-10365-5.

MLA (9th ed.) Citation

Aldardeer, Namareq F., et al. "Effectiveness of Traditional Non-carbapenem β-lactams Vs. Novel β-lactams for the Treatment of Carbapenem-resistant Pseudomonas Aeruginosa." BMC Infectious Diseases, vol. 24, no. 1, 2024, p. 1, https://doi.org/10.1186/s12879-024-10365-5.